SEC Form 4 · accession 0001144204-15-013701
DERMA SCIENCES, INC. · DSCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Wolfenson
Officer — See Remarks
Period of report
Feb 27, 2015
Accepted (ET)
Mar 3, 2015 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000892160
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2015 | M | 6,250 | $4.00 | A | 84,568 | D | |
| Common StockF1 | Feb 27, 2015 | F | 3,030 | $8.25 | D | 81,538 | D | |
| Common StockF2 | Mar 2, 2015 | A | 2,500 | $0.00 | A | 84,038 | D | |
| Common StockF3 | Mar 2, 2015 | F | 761 | $8.89 | A | 83,277 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $4.00 | Feb 27, 2015 | M | 6,250 | D | Feb 22, 2006 | Mar 1, 2015 | Common Stock | 6,250 | 0 | D |
Explanation of responses
- F1Shares delivered in connection with the cashless exercise of 6,250 options, previously granted pursuant to the issuer's stock option plan, at an exercise price of $4.00, as reported herein.
- F2Reflects the award of common stock pursuant to the grant of restricted stock units, previously reported on February 22, 2012. The restricted stock units issued pursuant to the issuer's restricted stock plan vest in three equal annual installments beginning on February 17, 2013.
- F3Shares withheld in connection with the vesting of 2,500 restricted share units, previously granted pursuant to the issuer's equity incentive plan at a closing price of $8.89, as reported herein.
- F4The options reported herein were issued under the issuer's stock option plan in consideration of the reporting person's services to the issuer granted on March 1, 2005, subject to the issuer's satisfaction of certain performance criteria for the fiscal year ending December 31, 2005, and further subject to continued employment through the vesting date. Certain of the performance criteria for 2005 were met, resulting in the vesting of 6,250 options.
- F5The options were originally granted in consideration of the reporting person's services to the issuer and without payment of cash.
Remarks
Group President, Advanced Wound Care & Pharmaceutical Development